Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
GuruMD directs patients away from costly emergency rooms and urgent cares by provi...
GuruMD directs patients away from costly emerge...
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...
Biocept, Inc. is a molecular diagnostics compan...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
InSitu Biologics is an emerging biotech company focusing on development of AnestaG...
InSitu Biologics is an emerging biotech company...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
Developing flexible and affordable genetic testing that improves the everyday live...
Developing flexible and affordable genetic test...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
Join the National Investor Network and get the latest information with your interests in mind.